Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system

Transfusion Medicine and Hemotherapy

Volumn 38, Issue 1, 2011, Pages 19-31

  Irsch, Johannes ^a   Lin, Lily ^b  

^a Cerus Europe BV   (Netherlands)

^b CERUS CORPORATION   (United States)

Author keywords

Amotosalen; Pathogen inactivation; Plasma; Platelets

Indexed keywords

AMOTOSALEN; FRESH FROZEN PLASMA; METHOXSALEN; TRIMETHYLPSORALEN;

ACCREDITATION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BACTERIUM; BLOOD COMPONENT; BLOOD SAFETY; BLOOD STORAGE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BLOOD VOLUME; BOVINE VIRAL DIARRHEA VIRUS; CHEMICAL STRUCTURE; CHIKUNGUNYA ALPHAVIRUS; CLINICAL STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DUCK HEPATITIS B VIRUS; ERYTHROCYTE; GAMMA IRRADIATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION PREVENTION; INFLUENZA VIRUS A H5N1; LEUKOCYTE; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; NONHUMAN; PARAMETER; PARASITE; PATHOGEN INACTIVATION; PATIENT SAFETY; PHOTODEGRADATION; PLASMA; PROTOZOON; SARS CORONAVIRUS; SPIROCHETE; TECHNOLOGY; THROMBOCYTE; TOXICOLOGY; ULTRAVIOLET A RADIATION; VIRUS ENVELOPE; VIRUS INACTIVATION; WEST NILE FLAVIVIRUS;

EID: 79851505189     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323937     Document Type: Article

References (60)

1. Alter HJ: Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008;22:97-102. (Pubitemid 351381952)
2. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F: Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007;47:2338-2347. (Pubitemid 350151213)
3. Wagstaff D: Dietary exposure to furocoumarins. Regul Toxicol Pharmacol 1991;14:261-272.
4. Shi Y, Lipson SE, Chi DY, et al: Applications of psoralens as probes of nucleic acid structure and function; in Morrison H (ed): Bioorganic Photo-chemistry and Nucleic Acids. New York, Wiley, 1990, pp 341-378.
5. Gottlieb SL, Wolfe JT, Fox FE, DeNardo BJ, Macey WH, Bromley PG, Lessin SR, Rook AH: Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996;35:946-957. (Pubitemid 26422119)
6. Honigsmann H: Phototherapy for psoriasis. Clin Exp Dermatol 2001;26:343-350. (Pubitemid 34204349)
7. Taylor A, Gasparro FP: Extracorporeal photoche-motherapy for cutaneous T-cell lymphoma and other diseases. Semin Hematol 1992;29:132-141.
8. Wollowitz S: Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001;38(suppl 11):4-11. (Pubitemid 33096553)
9. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L: Photochemical treatment of platelet concentrates with amotosalen and UVA inactivates a broad spectrum of patho-genic bacteria. Transfusion 2004;44:1496-1504. (Pubitemid 39318986)
10. van Rhenen D J, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L: Functional characteristics of S-59 photochemically treated platelet concentrates de-rived from buffy coats. Vox Sang 2000;79:206-214. (Pubitemid 32046032)
11. Knutson F, Alfonso R, Dupuis K, Mayaudon V, Lin L, Corash L, Hogman CF: Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000;78:209-216. (Pubitemid 30481251)
12. Terpstra FG, van't Wout AB, Schuitemaker H, van Engelenburg FA, Dekkers DW, Verhaar R, de Korte D, Verhoeven AJ: Potential and limitation of UVC irradiation for the inactivation of patho-gens in platelet concentrates. Transfusion 2008; 48:304-313.
13. Verhaar R, Dekkers DW, De Cuyper IM, Gins-berg MH, de Korte D, Verhoeven AJ: UV-C ir-radiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008;112:4935-4939.
14. Lozano M, Galan A, Mazzara R, Corash L, Escolar G: Leucocyte-reduced buffy coat derived platelet concentrates photochemically treated with amo-tosalen-HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion. 2006;47:666-671. (Pubitemid 46449627)
15. van Rhenen D, Gulliksson H, Cazenave JP, Pam-philon D, Ljungman P, Kluter H, Vermeij H, Ka-ppers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L: Transfusion of pooled buffy coat platelet com-ponents prepared with photochemical pathogen in-activation treatment: the euroSPRITE trial. Blood 2003;101:2426-2433. (Pubitemid 36302092)
16. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F, Davis K, Lin JS, Metzel P, Lin L, Koutsoukos A, Corash L, Buchholz DH, Conlan MG: Therapeutic efficacy and safety of platelets treated with a pho-tochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104:1534-1541. (Pubitemid 39166535)
17. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J: Therapeutic efficacy and safety of photochemi-cally treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45: 1443-1452. (Pubitemid 44194647)
18. Lozano M, Knutson F, Tardivel R, Cid J, Maymo R, Lof HM, Roddie HP, Pelly JP, Docherty AR, Sherman CD, Lin L, Propst M, Corash L, Prowse CV: A multi-center study of therapeutic efficacy and safety of platelet components prepared with pathogen inactivation (INTERCEPT) stored for 6 or 7 days prior to transfusion. Vox Sang 2010;99:13.
19. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient out-comes and component utilization during a 3-year period. Transfusion 2010;doi: 10.1111/j.1537-2995. 2010.02873.x.
20. Singh Y, Sawyer L, Pinkoski L, Dupuis K, Hsu J, Lin L, Corash L: Photochemical treatment of plasma with amotosalen and UVA light inactivates pathogens while retaining coagulation function. Transfusion 2006;46:1168-1177. (Pubitemid 44139491)
21. Irsch J, Pinkoski L, Corash L, Lin L: INTERCEPT plasma: comparability with conventional fresh-fro-zen plasma based on coagulation function-an in vitro analysis. Vox Sang 2010;98:47-55.
22. Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, Singh Y, Lin L, Corash L, Caze-nave JP: Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008;48:697-705. (Pubitemid 351430342)
23. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hamble-ton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Corash L, Wages D: Fresh fro-zen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation (PCT-FFP): transfusion of patients with congenital factor defi-ciencies. Transfusion 2005;45:1362-1372. (Pubitemid 41647805)
24. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, VanDoren S, Corash L: Photochemically treated fresh fro-zen plasma for transfusion of patients with ac-quired coagulopathy of liver disease. Blood 2006; 107:3753-3760.
25. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Roualt C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG: A randomized, controlled phase III trial of therapeutic plasma exchange with fresh frozen plasma prepared with amotosalen and UVA light compared to untreated fresh frozen plasma in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-1704. (Pubitemid 44435721)
26. Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Masse N, Osselaer JC: An active hemov-igilance program characterizing the safety profile of 7,483 transfusions with plasma components pre-pared with amotosalen and UVA photochemical treatment. Transfusion 2010;50:1210-1209.
27. de Valensart N, Rapaille A, Goossenaerts E, Sond-ag-Thull D, Deneys V: Study of coagulation func-tion in thawed apheresis plasma for photochemi-cal treatment by amotosalen and UVA. Vox Sang 2009;96:213-218.
28. Ciaravino V, McCullough T, Dayan AD: Pharma-cokinetic and toxicology assessment of INTER-CEPT (S-59 AND UVA treated) platelets. Hum Exp Toxicol 2001;20:533-550. (Pubitemid 34144864)
29. Tice RR, Gatehouse D, Kirkland D, Speit G: The pathogen reduction treatment of platelets with S-59 HCl (amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment. Mutat Res 2007;630:50-68. (Pubitemid 46756390)
30. Ciaravino V: Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective. Semin Hematol 2001;38(suppl 11):12-19. (Pubitemid 33096554)
31. Aster RH: Drug-induced immune thrombocytope-nia: an overview of pathogenesis. Semin Hematol 1999;36:2-6. (Pubitemid 29045503)
32. Cazenave JP, Ohlmann P, Isola H, Gachet C: Photochemical pathogen inactivation treatment of human plasma (amotosalen+ UVA) has no major impact on the protein pattern assessed by a 2-DIGE proteomic assay. Blood 2008;112:696.
33. Gasparro F, Chan G, Edelson RL: Phototherapy and photopharmacology. Yale J Biol Med 1985; 58:519-534. (Pubitemid 16142247)
34. Cimino GD, Gamper HB, Isaacs ST, Hearst JE: Psoralens as photoactive probes of nucleic acid structure and function: organic chemistry, photo-chemistry and biochemistry. Ann Rev Biochem 1985;54:1154-1193.
35. Lin L, Conlan MG, Tessman J, Cimino G, Por-ter S: Amotosalen interactions with platelet and plasma components: absence of neoantigen forma-tion after photochemical treatment. Transfusion 2005;45:1610-1620.
36. Corash L, Lin JS, Sherman CD, Eiden J: Deter-mination of acute lung injury following repeated platelet transfusions. Blood 2010; doi:10.1182/blood-2010-06-293399.
37. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L: A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemi-cal pathogen inactivation treatment. Transfusion 2008;48:1061-1071. (Pubitemid 351793479)
38. Osselaer JC, Cazenave JP, Lambermont M, Gar-raud O, Hidajat M, Barbolla L, Tardivel R, De-foin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L: An active haemov-igilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008;94:315-323. (Pubitemid 351535733)
39. Osselaer JC, Doyen C, Defoin L, Debry C, Gof-faux M, Messe N, Hooydonk MV, Bosly A, Lin JS, Lin L, Corash L: Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009;49:1412-1422.
40. Apelseth TO, Bruserud O, Wentzel-Larsen T, Hervig T: Therapeutic efficacy of platelet Transfusion in patients with acute leukemia: an evaluation of methods. Transfusion 2010;50:766-775.
41. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ: Clinical effectiveness of leucoreduced, pooled donor platelet concen-trates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010;150:209-217.
42. Slichter SJ, Davis K, Enright H, Braine H, Gern-sheimer T, Kao K, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R: Factors affecting posttransfusion platelet incre-ments, platelet refractoriness, and platelet Transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-4114. (Pubitemid 40656162)
43. Slichter SJ, Kaufman RM, Assmann SF, McCul-loough J, Triulzi DJ, Straus RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Sker-ett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S: Dose of prophylactic platelet transfusions and prevention of hemor-rhage. N Engl J Med 2010;362:600-613.
44. Mikovits J, Hagen K, Sadowski C, Ruscetti F, Liu W, Lin L: Inactivation of XMRV by the Intercept Blood System in platelet concentrates. Transfusion. 2010;50:211A.
45. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L: Inactivation of viruses in platelet concentrates by photochemi-cal treatment with amotosalen and long-wave-length ultraviolet light. Transfusion 2005;45:580-590.
46. Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP: Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009;49:1083-1091.
47. Nussbaumer W, Allersdorfer D, Grabmer C, Rheinschmidt M, Lin L, Schonitzer D, Lass-Florl C: Prevention of transfusion of platelet compo-nents contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inac-tivation methods. Transfusion 2007;47: 1125-1133. (Pubitemid 46934306)
48. Van Voorhis WC, Barrett LK, Eastman RT, Alfon-so R, Dupuis K: Trypanosoma cruzi inactivation in human platelet concentrates and plasma by psor-alen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003;47:475-479. (Pubitemid 36158069)
49. Grellier P, Benach J, Labaied M, Charneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Stei-ert M, Kupuis K: Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008;48:1676-1684.
50. Heddle NM, Kalma L, Singer J, Richards C, Fedak P, Walker I, Kelton JG: The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-628. (Pubitemid 24276861)
51. Muylle L, Joos M, Wouters E, Bock RD, Peeter-mens ME: Increased tumor necrosis factor alpha (TNF-alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored plateet concen-trates: relationship between TNF-alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993;33:195-199. (Pubitemid 23073640)
52. Grass JA, Hei DJ, Metchette K, Cimino GD, Wi-esehahn GP, Corash L, Lin L: Inactivation of leu-kocytes in platelet concentrates by psoralen plus UVA. Blood 1998;91:2180-2188. (Pubitemid 28185525)
53. Fiebig E, Hirschkorn DF, Maino VC, Grass JA, Lin L, Busch MP: Assessment of donor T-cell func-tion in cellular blood components by the CD69 induction assay: effects of storage, gamma irra-diation, and photochemical treatment. Transfusion 2000;40:761-770. (Pubitemid 30620676)
54. Truitt R, Johnson BD, Hanke C, Talib S, Hearst JE: Photochemical treatment with S-59 psor-alen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after al-logeneic bone marrow transplantation. J Immunol 1999;163:5145-5156. (Pubitemid 29501284)
55. Corash L, Lin L: Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004;33:1-7. (Pubitemid 38159696)
56. Schlenke P, Kirchner H, Corash L: Concerning Caspari et al: Pathogen inactivation of cellular blood products-more security for the patient or less? Transfus Med Hemother 2005;32:45-48. (Pubitemid 41218187)
57. Hei DJ, Grass J, Lin L, Corash L, Cimino G: Elimi-nation of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999;39:239-248. (Pubitemid 29144907)
58. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, Gettings KF, McLaughlin NJ, Silliman CC: Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the de-velopment of transfusion-related acute lung injury. Blood 2006;108:2455-2462. (Pubitemid 44497533)
59. Cognasse F, Osselaer JC, Payrat JM, Chavarin P, Corash L, Garraud O: Release of immune modu-lation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion 2008;48:809-813. (Pubitemid 351614918)
60. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S: Protecting the blood supplly from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19:110-126. (Pubitemid 40544291)